English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Aim of the study: As with other chronic diseases, depression is more prevalent among the patients with type 2 diabetes mellitus. Depression and diabetes-related distress adversely affect diabetes-related outcomes. This study aims at identifying comprehensive effects of antidepressant treatment in patients with type 2 diabetes mellitus and co-morbid depression. Material and methods: 124 subjects with type 2 diabetes mellitus were screened for depression using the Patient Health Questionnaire – 9 (PHQ-9). 34 subjects with PHQ score > 10 were recruited to the study and rated on Beck’s Depression Inventory (BDI), the Montgomery Asberg Depression Rating Scale (MADRS) and the Diabetes Distress Scale (DDS). Subjects’ glycemic parameters – Fasting Blood Sugar (FBS), Post-Prandial Blood Sugar (PPBS) and Glycated Hemoglobin (HbA1C) were recorded. All subjects were treated with either escitalopram or mirtazapine for a period of 8 weeks. Post-intervention changes in BDI, MADRS, DDS and glycemic parameters were noted. Results: Antidepressant treatment has led to a significant improvement in depressive symptoms (reduction in BDI: 19.13 ± 8.06; reduction in MADRS: 17.16 ± 5.3) and diabetes-related distress (reduction in DDS: 17.81 ± 8.93). Significant improvements were also noticed in glycemic parameters: FBS (p= 0.015) and HbA1C (p=0.004). Discussion: Distress in diabetes leads to poor self-care and higher HbA1C, while depression predicts poorer glycemic control, more complications and higher health-care costs. Improvement in depression and distress in diabetes yields much greater benefits. Conclusions: Antidepressant treatment with escitalopram or mirtazapine can effectively treat depression and reduce diabetes-related distress in patients with type 2 diabetes mellitus. Beneficial effects are noted on glycemic parameters as well.

Two birds with one stone: How depression and distress in diabetes respond to antidepressants